Abstract

Background Immunocompromised patients have lower seroconversion rate in response to COVID-19 vaccination. The aim of this study is to evaluate the humoral immune response with short-term clinical outcomes in solid organ transplant recipients vaccinated with SARS-CoV-2 vaccine (BBIBP-CorV; Sinopharm). Methods This prospective cohort was conducted from March to December 2021 in Abu Ali Sina hospital, Iran. All transplant recipients, older than 18 years were recruited. The patients received two doses of Sinopharm vaccine 4 weeks apart. Immunogenicity was evaluated through assessment of antibodies against the receptor-binding domain (RBD) of SARS-CoV-2 after the first and second dose of vaccine. The patients were followed up for 6 months after vaccination. Results Out of 921 transplant patients, 115 (12.5) and 239 (26) had acceptable anti S-RBD immunoglobulin G (IgG) levels after the first and second dose, respectively. Eighty patients (8.68) got infected with COVID-19 which led to 45 (4.9) of patients being hospitalized. None of the patients died during follow-up period. Twenty-four (10.9) liver transplant recipients developed liver enzyme elevation, and increased serum creatinine was observed in 86 (13.5) kidney transplant patients. Two patients experienced biopsy-proven rejection without any graft loss. Conclusion Our study revealed that humoral response rate of solid organ transplant recipients to Sinopharm vaccine was low. © 2023, The Author(s), under exclusive license to Springer Nature Switzerland AG.